Stoke Therapeutics, Inc. (STOK)
| Market Cap | 2.56B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.84M |
| Shares Out | 33.27M |
| EPS (ttm) | -2.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $69.06 |
| Previous Close | $69.81 |
| Change ($) | -0.75 |
| Change (%) | -1.07% |
| Day's Open | 69.65 |
| Day's Range | 68.82 - 71.58 |
| Day's Volume | 48,790 |
| 52-Week Range | 16.80 - 71.58 |
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...
Stoke Therapeutics is working in cutting edge science, however it is in early stages. It already has a very high valuation.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulati...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by prec...
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases, today announced...
As of late, it has definitely been a great time to be an investor Stoke Therapeutics, Inc. (STOK).
As of late, it has definitely been a great time to be an investor Stoke Therapeutics.
As of late, it has definitely been a great time to be an investor Stoke Therapeutics.
After top performance in August, the biotech was hit hard.
Stoke Therapeutics Inc. shares rocketed 46% in their trading debut Wednesday, after the company's initial public offering priced above its $14 to $16 price range.
Stoke Therapeutics, Inc. opened Wednesday morning at $27.21 per share.
About STOK
Stoke Therapeutics, an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001 used to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer genetic testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 an... [Read more...]
| Industry Biotechnology | IPO Date Jun 19, 2019 |
| CEO Edward Kaye | Employees 56 |
| Stock Exchange NASDAQ | Ticker Symbol STOK |
Analyst Forecasts
According to 9 analysts, the average rating for STOK stock is "Buy." The 12-month stock price forecast is 57.63, which is a decrease of -16.55% from the latest price.